Literature DB >> 11965121

[Ophthalmic manifestations of acute leukemia].

M Charif Chefchaouni1, M Belmekki, Z Hajji, H Tahiri, R Amrani, M El Bakkali, F Msefer Alaoui, A Berraho.   

Abstract

Orbital and ocular lesions are the third most frequent extramedullar locations of acute leukemia after the meninges and testicles. These lesions are treated as a central nervous system lesion; therefore diagnosis is essential to therapeutic adjustment. We present a retrospective study on charts of children treated for acute leukemia between 1996 and 1998. Ophthalmic examination was carried out when there were ocular symptoms. One hundred ninety-six children were treated for acute leukemia. Twelve children (6.1%) had an ocular and orbital lesion: 7 boys and 5 girls, with an average age of 6 years. Six had acute lymphoblastic leukemia, 6 had acute myeloid leukemia. Visual acuity was 1/10 in 9 children. Four children had an initial orbital lesion with a rapidly progressing exophthalmos. The hemogram and myelogram showed a granulocytic sarcoma. Two children who had been previously treated for acute leukemia presented a bilateral anterior uveitis with hypopyon; anterior chamber paracentesis showed blast cells and confirmed the ocular relapse. A corneal lesion was found in 2 children and in 2 cases, the optic nerve had edema; a decrease in visual acuity was the sign of the optic nerve lesion. Two patients had retinal infiltration with hemorrhages in the posterior pole. Prophylaxis consists of intrathecal injection of methotrexate and reinforcement of chemotherapy. Central nervous system irradiation is seldom used in children. Orbital and ocular lesions carry a poor prognosis according to the majority of authors. Two years after diagnosis of the ocular lesions, only 1 of the children studied remains alive.

Entities:  

Mesh:

Year:  2002        PMID: 11965121

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  9 in total

1.  Optic neuropathy as the first sign of central nervous system relapse in acute myeloid leukaemia: MRI findings and its diagnostic challenge.

Authors:  Michelle Cheung; Benjamin Fang; Raymand Lee
Journal:  BMJ Case Rep       Date:  2019-06-20

2.  Bilateral epibulbar granulocytic sarcomas: a case of an 8-year-old girl with acute myeloid leukaemia.

Authors:  Caroline Rosenberg; Paul T Finger; Louis Furlan; Codrin E Iacob
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-27       Impact factor: 3.117

3.  Ocular disorders in adult leukemia patients in Nigeria.

Authors:  Afekhide E Omoti; Caroline E Omoti; Rita O Momoh
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

4.  Ophthalmic manifestations of leukemia in a tertiary hospital population of adult nigerian africans.

Authors:  Boniface I Eze; Godswill O Ibegbulam; Sunday Ocheni
Journal:  Middle East Afr J Ophthalmol       Date:  2010-10

5.  Acute myelogenous leukemia mimicking fulminant periorbital cellulitis.

Authors:  Abbas Bagheri; Alireza Abrishami; Saeed Karimi
Journal:  J Ophthalmic Vis Res       Date:  2013-10

6.  Ophthalmic Manifestations of Newly Diagnosed Acute Leukemia Patients in a Tunisian Cohort.

Authors:  Jihene Sayadi; Dhouha Gouider; Yasmine Allouche; Racem Choura; Ines Cherni; Malek Sayadi; Hend Benneji; Imene Zghal; Ines Malek; Leila Nacef
Journal:  Clin Ophthalmol       Date:  2022-10-14

7.  Ophthalmic manifestations of acute and chronic leukemias presenting to a tertiary care center in India.

Authors:  Jacob Koshy; M Joseph John; Satish Thomas; Gurvinder Kaur; Nitin Batra; Wilson J Xavier
Journal:  Indian J Ophthalmol       Date:  2015-08       Impact factor: 1.848

8.  Acute Myeloid Leukemia Relapse Presenting as Complete Monocular Vision Loss due to Optic Nerve Involvement.

Authors:  Shyam A Patel
Journal:  Case Rep Hematol       Date:  2016-09-07

9.  Nonleukemic granulocytic sarcoma of orbit after blunt trauma: A case report and review of literature.

Authors:  Yuan Cheng; Chun'e Yu; Sha Zhu; Linghong Guo; Yi Zhang; Yiwen Zhang; Xuelei Ma
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.